FAAM-EUROBAT 2024 Concludes with Groundbreaking Advances in Food Allergy and Anaphylaxis Research
December 12, 2024 12:37 ET
|
European Academy of Allergy and Clinical Immunology
ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share...
EAACI to Launch World Anaphylaxis Awareness Day on 21 November at FAAM-EUROBAT 2024
November 13, 2024 05:43 ET
|
European Academy of Allergy and Clinical Immunology
On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!
Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment
November 05, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.
EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management
October 30, 2024 07:26 ET
|
European Academy of Allergy and Clinical Immunology
The European Academy of Allergy and Clinical Immunology (EAACI) has released updated "Clinical Guidelines on the Management of IgE-mediated Food Allergy."
Food Allergy Market Report 2024: $40+ Billion Industry to Grow at a CAGR of 6.7% During 2025-2030 - Innovations in Immunotherapy allergology Open New Avenues in Treatment
October 22, 2024 09:00 ET
|
Research and Markets
Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Food Allergy Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Allergen Source, Treatment Type, Channel, Region, By...
Insignis Therapeutics Announces Positive Results from Phase 1 Clinical Study of IN-001 Liquid Epinephrine Sublingual Spray for Anaphylaxis
October 07, 2024 08:00 ET
|
Insignis Therapeutics, Inc.
Insignis' Phase 1 trial shows IN-001 spray quickly reaches target epinephrine levels, sustained for 2 hours, offering a reliable needle-free alternative.
Allergy Treatment Market Size and Share Projected to Surpass USD 34.9 Billion by 2034 at 5.8% CAGR - Report by Transparency Market Research, Inc.
September 05, 2024 11:54 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc., Sept. 05, 2024 (GLOBE NEWSWIRE) -- The projected allergy treatment market (알레르기 치료 시장) growth will drive the market to reach...
Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
August 13, 2024 07:30 ET
|
Insignis Therapeutics, Inc.
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
United States Food Allergen Testing Market Forecast Report 2024: A $422.67 Million Industry by 2032 with PCR and ELISA Technologies Leading the Way
August 06, 2024 04:04 ET
|
Research and Markets
Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "United States Food Allergen Testing Market Forecast Report By Food Testing, Technology, States and company analysis 2024-2032" report has been added to...
Global Food Allergy and Intolerance Products Strategic Analysis Report 2024-2030: Advancements in Food Technology and Ingredient Innovation Drive Development of Allergen-Free Alternatives
July 26, 2024 07:06 ET
|
Research and Markets
Dublin, July 26, 2024 (GLOBE NEWSWIRE) -- The "Food Allergy and Intolerance Products - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...